Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature

Autor: Carlo Chizzolini, Laurent Arnaud, Patricia Senet, Camille Francès, François Chasset, Hélène Traineau, Annick Barbaud, Jean-Benoît Monfort, Rohit Aggarwal, Chester V. Oddis
Přispěvatelé: Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immuno-Rhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), CCSD, Accord Elsevier, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Geneva University Hospital (HUG), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS)
Rok vydání: 2019
Předmět:
medicine.medical_specialty
systemic sclerosis
[SDV]Life Sciences [q-bio]
Dermatologic Surgical Procedures
Thiosulfates
Dermatology
ddc:616.07
Cochrane Library
Injections
Intralesional
Skin Diseases
Dermatomyositis
law.invention
Calcinosis cutis
030207 dermatology & venereal diseases
03 medical and health sciences
Diltiazem
0302 clinical medicine
Randomized controlled trial
law
medicine
Humans
skin and connective tissue diseases
Juvenile dermatomyositis
Physical Therapy Modalities
Randomized Controlled Trials as Topic
ddc:616
Scleroderma
Systemic
integumentary system
business.industry
Calcinosis
level of evidence
Retrospective cohort study
Evidence-based medicine
medicine.disease
3. Good health
[SDV] Life Sciences [q-bio]
Treatment Outcome
030220 oncology & carcinogenesis
Rituximab
business
calcinosis cutis
medicine.drug
Zdroj: Journal of The American Academy of Dermatology
Journal of The American Academy of Dermatology, Elsevier, 2020, 82, pp.317-325. ⟨10.1016/j.jaad.2019.07.006⟩
Journal of the American Academy of Dermatology (2019)
Journal of The American Academy of Dermatology, 2020, 82 (2), pp.317-325. ⟨10.1016/j.jaad.2019.07.006⟩
ISSN: 1097-6787
0190-9622
Popis: International audience; Background: We have limited data on the treatment of calcinosis cutis associated with systemic sclerosis and dermatomyositis.Objective: To assess the efficacy and tolerance of available treatments for calcinosis cutis based on previously published studies.Methods: We performed a systematic review of studies published in Medline, Embase, and the Cochrane library during 1980-July 2018. The strength of clinical data was graded according to the modified Oxford Centre for Evidence-Based Medicine levels of evidence.Results: In all, 30 studies (288 patients) were included. Eleven therapeutic classes, surgery, and physical treatments were identified as potential treatment options for calcinosis cutis. On the basis of results of a small randomized controlled trial and 4 retrospective studies, low-dose warfarin should not be used for calcinosis cutis (level IB evidence). The results of several studies suggest diltiazem and bisphosphonates might be useful treatment options (level IV). Considering biologic therapies, rituximab has shown promising results in treating both dermatomyositis and systemic sclerosis, whereas tumor necrosis factor inhibitors might be useful for treating juvenile dermatomyositis (level IV). Intralesional sodium thiosulfate might be a promising alternative (level IV).Limitations: Few included studies had a high level of evidence.Conclusion: This study highlights the efficacy and tolerance profiles of available treatments for calcinosis cutis, with a focus on level of evidence.
Databáze: OpenAIRE
Externí odkaz: